Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
Portfolio Pulse from
Acadia Pharmaceuticals has agreed to sell its Rare Pediatric Disease Priority Review Voucher for $150 million. The voucher was granted after the FDA approved DAYBUE for Rett syndrome treatment.
November 05, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Acadia Pharmaceuticals is selling its Rare Pediatric Disease Priority Review Voucher for $150 million. This sale follows the FDA's approval of DAYBUE for Rett syndrome.
The sale of the PRV for $150 million provides a significant cash inflow for Acadia Pharmaceuticals, which could positively impact its stock price. The FDA approval of DAYBUE and the subsequent sale of the voucher highlight the company's successful product development and monetization strategy.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100